Modus Therapeutics Holding AB operates as a biotechnology company. It develops sevuparin with a focus on diseases with a high unmet medical need. The firm focuses to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal condition. The company was founded in 2011 and is headquartered in Stockholm, Sweden.